Medpace Holdings Inc (NASDAQ:MEDP) CEO August J. Troendle sold 84,093 shares of the stock in a transaction on Friday, February 1st. The stock was sold at an average price of $65.54, for a total value of $5,511,455.22. Following the completion of the sale, the chief executive officer now owns 603,702 shares of the company’s stock, valued at approximately $39,566,629.08. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Shares of Medpace stock opened at $66.51 on Wednesday. The stock has a market cap of $2.41 billion, a PE ratio of 43.76, a PEG ratio of 1.44 and a beta of 1.76. The company has a quick ratio of 0.66, a current ratio of 0.66 and a debt-to-equity ratio of 0.25. Medpace Holdings Inc has a twelve month low of $31.75 and a twelve month high of $69.71.
MEDP has been the subject of a number of analyst reports. SunTrust Banks upgraded Medpace from a “hold” rating to a “buy” rating and set a $63.00 price target for the company in a research note on Wednesday, October 31st. They noted that the move was a valuation call. BidaskClub lowered Medpace from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 31st. Zacks Investment Research upgraded Medpace from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a research report on Thursday, November 1st. Finally, ValuEngine lowered Medpace from a “buy” rating to a “hold” rating in a research report on Thursday, December 6th. Five investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $44.43.
Institutional investors have recently modified their holdings of the company. LS Investment Advisors LLC purchased a new position in shares of Medpace during the fourth quarter valued at about $46,000. State of Alaska Department of Revenue purchased a new position in shares of Medpace during the fourth quarter valued at about $92,000. We Are One Seven LLC purchased a new position in shares of Medpace during the fourth quarter valued at about $130,000. Great West Life Assurance Co. Can grew its position in shares of Medpace by 270.1% during the third quarter. Great West Life Assurance Co. Can now owns 3,331 shares of the company’s stock valued at $200,000 after purchasing an additional 2,431 shares in the last quarter. Finally, Legal & General Group Plc grew its position in shares of Medpace by 78.6% during the third quarter. Legal & General Group Plc now owns 3,436 shares of the company’s stock valued at $206,000 after purchasing an additional 1,512 shares in the last quarter. Hedge funds and other institutional investors own 72.44% of the company’s stock.
Medpace Company Profile
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Featured Story: What is Compound Interest?
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.